INT275080

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.11
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Twist1) nucleus (Twist1) DNA binding (Twist1)
transcription factor binding (Twist1)
Twist1 (Mus musculus)
Pain Link Frequency Relevance Heat
long-term potentiation 106 5.00 Very Low Very Low Very Low
Hippocampus 18 5.00 Very Low Very Low Very Low
depression 16 5.00 Very Low Very Low Very Low
Neurotransmitter 16 5.00 Very Low Very Low Very Low
Central nervous system 8 5.00 Very Low Very Low Very Low
nMDA receptor 4 5.00 Very Low Very Low Very Low
antidepressant 4 5.00 Very Low Very Low Very Low
ischemia 4 5.00 Very Low Very Low Very Low
Glutamate 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cognitive Disorder 188 56.00 Quite High
Targeted Disruption 30 10.88 Low Low
Anxiety Disorder 24 5.00 Very Low Very Low Very Low
Depression 16 5.00 Very Low Very Low Very Low
Disease 14 5.00 Very Low Very Low Very Low
Schizophrenia 12 5.00 Very Low Very Low Very Low
Aging 12 5.00 Very Low Very Low Very Low
Shock 8 5.00 Very Low Very Low Very Low
Vomiting 8 5.00 Very Low Very Low Very Low
Diabetes Mellitus 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
PDE inhibitors (PDE-Is) increase the intracellular amount of cAMP and/or cGMP by inhibiting the enzymatic degradation of these second messengers, dependent on the substrate specificity of the corresponding PDE (see also TableĀ 2).
Positive_regulation (increase) of Negative_regulation (inhibitors) of PDE
1) Confidence 0.05 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.06 Pain Relevance 0
PDE inhibitors (PDE-Is) increase the intracellular amount of cAMP and/or cGMP by inhibiting the enzymatic degradation of these second messengers, dependent on the substrate specificity of the corresponding PDE (see also TableĀ 2).
Positive_regulation (increase) of Negative_regulation (inhibitors) of PDE
2) Confidence 0.04 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox